Table of Contents

When managing chronic conditions like type 2 diabetes or obesity, two of the medications that frequently come up are Trulicity and Wegovy. Each has a distinct purpose, different active ingredients, and unique effects on your body. Choosing between the two can depend on various factors, ranging from your health goals to side effect tolerance, insurance coverage, and more.

This guide outlines ten essential factors to help you decide between Trulicity vs. Wegovy. Know which medication might work best for your unique health needs.

Key Takeaways

  • Your health condition matters most when choosing. Trulicity is mainly for people with type 2 diabetes who also need heart protection. Wegovy is designed for weight loss in people with obesity, even if they don’t have diabetes.
  • Wegovy delivers stronger weight loss results. Across studies, Wegovy leads to more pounds lost, more body fat reduced, and greater changes in BMI than Trulicity.
  • Both medications cause nausea and vomiting, but fewer people stop using Trulicity due to side effects, making it easier to tolerate long-term.
  • Trulicity’s injection device is more user-friendly, which can make a big difference for those new to injections.
  • Because it’s a diabetes drug, Trulicity is often better covered by insurance plans than Wegovy, which is treated as a weight-loss drug and not always included in benefits.
  • Wegovy may carry more mental health risks. Some users report mood-related side effects with Wegovy, and doctors may avoid it for people with a history of depression or suicidal thoughts.

1. Approved Medical Uses

Trulicity (dulaglutide) is approved by the FDA primarily for treating type 2 diabetes. It also reduces cardiovascular (CV) risks in diabetic patients with heart-related concerns. Multiple studies have demonstrated Trulicity’s effectiveness.

In a long-term study involving a large database of US adults with type 2 diabetes, Trulicity effectively helped nearly half of patients achieve an HbA1c level below 7% (indicating good diabetes management), while about three-quarters reached levels below 8%.

Wegovy (semaglutide), on the other hand, is specifically FDA-approved for chronic weight management in individuals who have obesity or are overweight with related health issues like hypertension or high cholesterol.

Clinical trials have shown substantial and sustained weight loss with Wegovy, making it one of the most effective prescription medications currently available for long-term weight management.

If blood sugar control and heart health are your main concerns, particularly related to type 2 diabetes, Trulicity is typically more suitable. However, if your goal is substantial and sustained weight reduction, even without diabetes, Wegovy is likely the optimal choice due to its superior efficacy in promoting significant weight loss.

2. Weight Loss Potential

Doctor measuring patients belly fat

While both medications aid in weight loss, their effectiveness differs significantly. Across multiple comparative studies, Wegovy consistently showed greater success than Trulicity in reducing body weight.

Researchers found semaglutide to be more effective in the following areas:

    • Total weight lost
    • Chances of losing up to 10% of body weight
    • Lowering BMI

A 2021 study found that people with type 2 diabetes taking semaglutide 1.0 mg lost 2.65 kg (5.8 lbs) more than those on dulaglutide 3.0 mg, and 1.95 kg (4.3 lbs) more than those on dulaglutide 4.5 mg.

In a real-world study, patients on dulaglutide lost an average of 5.63 kg, while those on semaglutide lost 7.6 kg. A separate meta-analysis confirmed semaglutide’s superior weight-loss effect.

If you want to lose a significant amount of weight and don’t have type 2 diabetes, Wegovy may be a more effective option. But if you’re focused on managing diabetes while also losing some weight, Trulicity may be a better fit. Even small weight loss can help improve blood sugar in people with type 2 diabetes.

3. Active Ingredients

Trulicity contains dulaglutide, while Wegovy contains semaglutide. Although both medications belong to the same drug class, their molecular makeup influences how they interact with your body’s GLP-1 receptors.

Which Is Absorbed Better?

After a shot under the skin, both semaglutide and dulaglutide take about 24 to 72 hours to reach peak levels in your blood. However, dulaglutide becomes stable in your system after 2 to 4 weeks of once-a-week use, while steady levels of semaglutide are seen after 4-5 weeks of weekly injections. Still, semaglutide is absorbed more efficiently than dulaglutide, with a higher bioavailability (89% vs. 65%).

Which Spreads Through the Body More?

Dulaglutide spreads through a slightly larger volume of body fluids (about 17-19 L), while semaglutide spreads a bit less (12.5 L). Both mainly stay in the bloodstream.

Which Stays in the Body Longer?

Semaglutide lasts longer. Its half-life is around 7 days, compared to 5 days for dulaglutide. Semaglutide also remains in the body up to 5 weeks after the last dose.

Keep in mind: While these numbers offer useful comparisons, how your body responds can vary. Individual factors like metabolism, health conditions, and other medications can influence how each drug works for you.

4. Dosing and Titration Differences

Both Trulicity and Wegovy require weekly injections but differ significantly in their dosing strategies. Wegovy starts at a very low dose, 0.25 mg once a week, to help your body adjust and minimize side effects. It would take about 16-20 weeks to reach the full maintenance dose (2.4 mg).

The starting dose of Trulicity is already higher than Wegovy’s first dose (0.75 mg once a week). It only takes 15 weeks to reach the maximum dose of 4.5 mg weekly.

Here is a comparison of the dosing schedules for Wegovy and Trulicity:

Medication Starting Dose Titration Dose Maximum Dose
Month 1 Month 2 Month 3 Month 4 Month 5+
Wegovy (semaglutide) 0.25 mg once weekly 0.25 mg per week 0.5 mg per week 0.5-1.0 mg per week 1.0-1.7 mg per week 1.0-2.4 mg per week 2.4 mg once weekly
Trulicity (dulaglutide) 0.75 mg once weekly 0.75 mg per week 1.5 mg per week 1.5-3.0 mg per week 3.0-4.5 mg per week 3.0-4.5 mg per week 4.5 mg once weekly

While these are standard guidelines, your doctor may adjust your dose schedule based on how your body reacts. Side effects, weight loss goals, or blood sugar levels can all influence how quickly or slowly the dose is increased.

5. Side Effect Profiles

Gastrointestinal side effects like nausea, diarrhea, and vomiting are common for both medications. However, Wegovy users generally report higher rates and intensity of these side effects, especially during the initial dosage escalation.

In separate placebo-controlled trials, up to 44% of patients treated with Wegovy experienced nausea, compared to 16.4% of those treated with Trulicity. A higher percentage of patients on Wegovy 2.4 mg (6.8%) permanently discontinued treatment due to side effects, while only up to 3.5% of Trulicity users stopped treatment for the same reason.

Outside of clinical trials, comparative studies are mixed. One study found that semaglutide caused more nausea and vomiting than other GLP-1 drugs. But another study didn’t find a difference in stomach side effects between semaglutide and other similar drugs like dulaglutide. In terms of serious side effects, researchers found no major differences between semaglutide and dulaglutide.

If gastrointestinal discomfort is a significant concern, Trulicity typically has a milder side effect profile, making it potentially easier to tolerate.

6. Cardiovascular Benefits

Elderly patient speaking to cardiologist

Both Trulicity and Wegovy offer cardiovascular benefits, but the strength and focus of the supporting evidence differ.

In the REWIND trial, Trulicity was shown to reduce the risk of major cardiovascular events (MACE) by 12% compared to placebo. On the other hand, the SELECT trial found that Wegovy reduced the risk of MACE by 20%.

That said, your eligibility will depend on each drug’s approved use. If you have type 2 diabetes and need both heart protection and blood sugar control, Trulicity may be the more appropriate option. But if you have obesity with established cardiovascular disease, even without diabetes, your doctor may recommend Wegovy instead.

7. Insurance Coverage and Affordability

If you’re in the US, Trulicity and Wegovy may cost quite a bit, especially without insurance coverage. Based on manufacturer pricing, Trulicity costs $987.19 for a 30-day supply. Wegovy costs around $1,349.02 for the same supply. Retail prices at some pharmacies even go beyond $1,200.

Insurance plans often differ significantly regarding coverage for Trulicity and Wegovy. Trulicity, primarily a diabetes medication, generally enjoys broader coverage. However, it’s often classified as a Tier 3 medication, which may result in higher copayments or coinsurance compared to lower-tier drugs.

Wegovy, classified strictly as a weight loss drug, frequently faces insurance coverage challenges. Traditional Medicare (Part A and B) and state Medicaid programs generally do not cover prescription weight-loss medications.

Here are some steps to help you determine whether your insurance covers Wegovy or Trulicity:

    • Review Your Health Plan’s Formulary: Check the list of medications covered by your insurance plan to see what medications are included. This list can usually be found on your insurer’s website or by calling their customer support line.
    • Inquire About Prior Authorization Requirements: Some insurance companies require prior authorization for Wegovy or Trulicity. This process involves your healthcare provider submitting documentation to show that the drug is medically necessary for your condition. Prior authorization requirements vary, so it’s best to speak with both your provider and insurance company to understand any necessary steps.
    • Coverage Through Employer-Sponsored Plans: If you receive health insurance through your employer, you may want to inquire if they offer any specific support for GLP-1 medications.

Save with Pharma Giant!

Pharma Giant, a Canadian-based online pharmacy service, provides a more budget-friendly alternative:

Ordering in bulk (up to a 3-month supply) can further reduce costs, and discount coupons for Trulicity and Wegovy are also available.

8. User-Friendly Injection Devices

Convenience and ease of use matter greatly, especially if you’re uncomfortable with injections. In one study, 84.2% of participants favored the dulaglutide injection device, while only 12.3% preferred the semaglutide option. When asked about ease of use, 86.8% said dulaglutide was simpler to use, compared to just 6.8% who felt that way about semaglutide.

Training time also differed significantly. On average, it took under 4 minutes to train someone to use the dulaglutide pen, while the semaglutide pen required more than 8 minutes.

A separate study has similar findings. Among three GLP-1 injection pens tested, the dulaglutide device ranked highest in user satisfaction, ease of use, and speed, taking just 69 seconds to complete an injection. About 75% of participants chose it as their preferred device.

This can influence whether you stick with the medication long-term. A simpler, more user-friendly device like Trulicity’s may help reduce anxiety around injections, improve adherence, and make weekly dosing feel less burdensome, especially if you’re new to self-injecting.

9. Impact on Mental Health and Motivation

Elderly woman suffering from depression

Some weight-loss medications, including those similar to Wegovy, have been linked to suicidal thoughts or behaviors in clinical trials. Because of this, your doctor will likely monitor you for any signs of worsening depression, unusual mood changes, or thoughts of self-harm while you’re taking Wegovy.

Wegovy also isn’t recommended if you’ve ever attempted suicide or are currently experiencing suicidal thoughts.

Researchers analyzed a large international safety database called VigiBase®, which tracks real-world reports of side effects. Out of over 2 million reports, around 21,000 mentioned psychiatric issues linked to GLP-1 drugs. For semaglutide specifically, there were slightly higher-than-expected reports of anxiety, depression, and suicidality.

Emotional well-being is a part of your health picture. You and your doctor might lean toward Trulicity as the safer option.

10. Impact on Metabolic Syndrome Components

Wegovy has shown improvements not only in weight but also in blood pressure, lipid levels, and waist circumference. While Trulicity improves metabolic syndrome through glucose control, its impact on other components may not be as strong.

In studies, semaglutide helps people lose fat, especially dangerous belly fat (visceral fat), while helping preserve lean muscle mass. It reduced total fat mass and visceral fat by a few percentage points, while the percentage of lean muscle actually went up.

Semaglutide also stood out as the only GLP-1 drug that lowered both LDL (“bad”) cholesterol and total cholesterol meaningfully. Additionally, people taking semaglutide reported feeling less hungry, becoming fuller faster, and eating less, even when allowed to eat as much as they wanted.

To Sum It Up

Trulicity is better if you have type 2 diabetes and need to lower blood sugar while protecting your heart. It’s easier to use, has fewer stomach-related side effects, and is often covered by insurance.

Wegovy is the stronger option if your main goal is weight loss. It helps shed more pounds, cuts belly fat, improves cholesterol, and reduces hunger. But it’s more likely to cause nausea and vomiting, and can be harder to get insurance coverage for.

Your health goals, tolerance for side effects, and insurance coverage will determine which is the right choice. As always, decisions should be made with your healthcare provider, considering your full medical history and personal goals.

Frequently Asked Questions

Both Trulicity (dulaglutide) and Mounjaro (tirzepatide) help manage type 2 diabetes, but Mounjaro often leads to greater A1C reduction and weight loss. That’s because it targets both GIP and GLP-1 receptors, while Trulicity works only on GLP-1.

As of now, Zepbound (tirzepatide) is the most effective FDA-approved GLP-1-related drug for weight loss. In trials, patients lost up to 21% of their body weight on the highest dose. Wegovy (semaglutide 2.4 mg) is also approved and highly effective, with average weight loss around 15%.

Both Trulicity and Ozempic are once-weekly injections, so to maintain steady medication levels and avoid overlap or gaps, you simply take your last Trulicity injection as scheduled. Exactly 7 days later, take your first Ozempic 0.25 mg injection on the same day of the week. Always confirm with your doctor before switching, as individual plans may vary slightly.

Ozempic and Wegovy both contain semaglutide, but in different doses. Wegovy is stronger for weight loss because it’s prescribed at 2.4 mg weekly, while Ozempic’s highest dose is 2 mg. So, it’s not about one being weaker, it depends on the dosage and purpose (diabetes vs. weight loss).

Most side effects, like nausea, bloating, or diarrhea, tend to improve within a few weeks as your body adjusts. Some people tolerate the medication better over time. If symptoms persist beyond a month or become severe, talk to your doctor about adjusting your dose or switching treatments.

Trulicity users may lose between 6-10 pounds (about 3-5% of body weight), especially at higher doses like 3.0 mg or 4.5 mg. However, weight loss varies and is considered a secondary benefit, as Trulicity is primarily approved to control blood sugar and lower cardiovascular risk.

Trulicity isn’t recommended for people with a personal or family history of medullary thyroid cancer or MEN 2 syndrome. It’s also not advised if you’ve had serious allergic reactions to dulaglutide. Your doctor may also avoid it if you have severe stomach or kidney problems.

Related Articles

Sources

Mody, R., Yu, M., Grabner, M., Boye, K., Teng, C., & Kwan, A. Y. (2020). Dulaglutide shows sustained reduction in glycosylated hemoglobin values: 2-Year US Real-world study results. Clinical Therapeutics, 42(11), 2184–2195. https://doi.org/10.1016/j.clinthera.2020.09.011

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., Xavier, D., Atisso, C. M., Dyal, L., Hall, S., Rao-Melacini, P., Wong, G., Avezum, A., Basile, J., Chung, N., . . . Zigrang, W. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet, 394(10193), 121–130. https://doi.org/10.1016/s0140-6736(19)31149-3

Pratley, R. E., Catarig, A., Lingvay, I., Viljoen, A., Paine, A., Lawson, J., Chubb, B., Gorst?Rasmussen, A., & Miresashvili, N. (2021). An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg. Diabetes Obesity and Metabolism, 23(11), 2513–2520. https://doi.org/10.1111/dom.14497

Tofé, S., Argüelles, I., Mena, E., Serra, G., Codina, M., Urgelés, J. R., García, H., & Pereg, V. (2021). An observational study evaluating effectiveness and therapeutic adherence in patients with Type 2 Diabetes initiating dulaglutide vs. subcutaneous semaglutide in Spain. Endocrine and Metabolic Science, 2, 100082. https://doi.org/10.1016/j.endmts.2021.100082

Xia, L., Li, H., Huang, S., & Shen, L. (2024). Semaglutide vs. dulaglutide for glycemic and weight control in patients with type 2 diabetes mellitus: A systematic review and meta?analysis. Biomedical reports, 22(3), 35. https://doi.org/10.3892/br.2024.1913

Smith, L. L., Mosley, J. F., II, Parke, C., Brown, J., Barris, L. S., & Phan, L. D. (2016, June 1). Dulaglutide (Trulicity): the third Once-Weekly GLP-1 agonist. https://pmc.ncbi.nlm.nih.gov/articles/PMC4894510/

Kommu, S., & Whitfield, P. (2024, February 11). Semaglutide. StatPearls – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK603723/

Mishriky, B., Cummings, D., Powell, J., Sewell, K., & Tanenberg, R. (2018). Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes & Metabolism, 45(2), 102–109. https://doi.org/10.1016/j.diabet.2018.09.002

Shi, F., Li, H., Cui, M., Zhang, Z., Gu, Z., & Liu, X. (2018). Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Pharmacology, 9. https://doi.org/10.3389/fphar.2018.00576

Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/nejmoa2307563

Matza, L. S., Boye, K. S., Stewart, K. D., Coyne, K. S., Wullenweber, P. K., Cutts, K. N., Jordan, J. B., Wang, Q., Yu, M., Currie, B. M., Malley, K. G., Ishak, K. J., Hietpas, R. T., & García-Pérez, L. E. (2020). Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER). Diabetes, obesity & metabolism, 22(3), 355–364. https://doi.org/10.1111/dom.13902

Wettergreen, S. A., Stewart, M. P., Kennedy, K., & Trujillo, J. M. (2022). Comparison of the usability, accuracy, preference, and satisfaction of three Once-Weekly Glucagon-Like Peptide 1 Receptor Agonist PEN devices in people with Type 2 diabetes. Diabetes Spectrum, 36(1), 5–13. https://doi.org/10.2337/ds21-0108

Nishida, K., Chrétien, B., Dolladille, C., Ebina, T., Aleksic, B., Cabé, N., Savey, V., Onoue, T., & Yatsuya, H. (2025). Psychiatric and Psychological Adverse Effects Associated with Dulaglutide, Semaglutide, and Liraglutide: A Vigibase Study. Clinical Nutrition. https://doi.org/10.1016/j.clnu.2025.06.011

Sokary, S., & Bawadi, H. (2025). Exploring beyond numeric weight loss: the metabolic effects of semaglutide. Clinical Nutrition ESPEN. https://doi.org/10.1016/j.clnesp.2025.03.010